Review



igf2 contents  (Cusabio)


Bioz Verified Symbol Cusabio is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cusabio igf2 contents
    Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as assessed by impedance measurements. N = 4, average SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control), P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or <t>Igf2-silenced</t> pericytes. N = 5, average SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media) (ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR with GAPDH as housekeeping gene. N = 3, average SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test).
    Igf2 Contents, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf2 contents/product/Cusabio
    Average 93 stars, based on 12 article reviews
    igf2 contents - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation."

    Article Title: Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation.

    Journal: Molecular oncology

    doi: 10.1002/1878-0261.12752

    Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as assessed by impedance measurements. N = 4, average SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control), P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or Igf2-silenced pericytes. N = 5, average SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media) (ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR with GAPDH as housekeeping gene. N = 3, average SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test).
    Figure Legend Snippet: Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as assessed by impedance measurements. N = 4, average SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control), P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or Igf2-silenced pericytes. N = 5, average SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media) (ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR with GAPDH as housekeeping gene. N = 3, average SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test).

    Techniques Used: In Vitro, Control, Cell Culture, Expressing, Comparison



    Similar Products

    igf2 contents  (Cusabio)
    93
    Cusabio igf2 contents
    Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as assessed by impedance measurements. N = 4, average SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control), P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or <t>Igf2-silenced</t> pericytes. N = 5, average SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media) (ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR with GAPDH as housekeeping gene. N = 3, average SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test).
    Igf2 Contents, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf2 contents/product/Cusabio
    Average 93 stars, based on 1 article reviews
    igf2 contents - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as assessed by impedance measurements. N = 4, average SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control), P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or Igf2-silenced pericytes. N = 5, average SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media) (ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR with GAPDH as housekeeping gene. N = 3, average SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test).

    Journal: Molecular oncology

    Article Title: Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation.

    doi: 10.1002/1878-0261.12752

    Figure Lengend Snippet: Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as assessed by impedance measurements. N = 4, average SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control), P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or Igf2-silenced pericytes. N = 5, average SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media) (ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR with GAPDH as housekeeping gene. N = 3, average SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average SD, *P < 0.05 (ANOVA and Bonferroni’s post hoc test).

    Article Snippet: Insulin-like growth factor 1 (IGF1) and IGF2 contents of conditioned media were measured using commercial ELISA kits (CSB-E04580h and CSB-E04583h, respectively; Cusabio, Wuhan, China) following the manufacturer’s instructions.

    Techniques: In Vitro, Control, Cell Culture, Expressing, Comparison